Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Non Operating Income (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Non Operating Income readings, the most recent being -$681000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 6090.91% year-over-year to -$681000.0, compared with a TTM value of -$146000.0 through Dec 2025, down 117.7%, and an annual FY2025 reading of -$145000.0, up 43.58% over the prior year.
  • Non Operating Income hit -$681000.0 in Q4 2025 for Lisata Therapeutics, down from $165000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $2.7 million in Q4 2023, with the low at -$681000.0 in Q4 2025.
  • Median Non Operating Income over the past 3 years was $163000.0 (2025), compared with a mean of $323833.3.
  • The sharpest move saw Non Operating Income soared 3192.31% in 2024, then plummeted 6090.91% in 2025.
  • Year by year, Non Operating Income stood at $2.7 million in 2023, then crashed by 100.41% to -$11000.0 in 2024, then crashed by 6090.91% to -$681000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$681000.0, $165000.0, and $209000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.